Hormone replacement therapy and the risk of breast cancer

European Journal of Cancer

Volumn 44, Issue 16, 2008, Pages 2344-2349

  Cuzick, Jack ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Breast cancer risk; Hormone replacement therapy; Oestrogen therapy; Progestagens

Indexed keywords

CALCIUM; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; TIBOLONE; VITAMIN D;

ARTICLE; BREAST CANCER; CANCER RISK; COLORECTAL CANCER; DEMENTIA; ENDOMETRIUM CANCER; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; PILL; PRIORITY JOURNAL; STROKE; UNITED STATES;

AGED; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; PROGESTINS; RISK FACTORS; WOMEN'S HEALTH;

EID: 54249150343     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.07.041     Document Type: Article

References (26)

1. Watkins E.S. The estrogen elixir. A history of hormone replacement therapy in America (2007), The Johns Hopkins University Press, Baltimore
2. Smith D.C., Ross M.D., Donovan P.D., et al. Association of exogenous estrogen and endometrial carcinoma. N Engl JMed 293 23 (1975) 1164-1167
3. Weiss N.S., Szekely D.R., and Austin D.F. Increasing incidence of endometrial cancer in the United States. N Engl J Med 294 23 (1976) 1259-1262
4. Hoover R., Gray Sr. L.A., Cole P., and MacMahon B. Menopausal estrogens and breast cancer. N Engl J Med 295 8 (1976) 401-405
5. Hunt K., Vessey M., McPherson K., and Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 94 7 (1987) 620-635
6. Gambrell Jr. R.D., Maier R.C., and Sanders B.I. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 62 4 (1983) 435-443
7. Colditz G.A., Hankinson S.E., Hunter D.J., et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332 24 (1995) 1589-1593
8. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350 9084 (1997) 1047-1059
9. van den Brandt P.A., Spiegelman D., Yaun S.S., et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 152 6 (2000) 514-527
10. Holli K., Isola J., and Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 16 9 (1998) 3115-3120
11. Beral V., and Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 9382 (2003) 419-427
12. Chlebowski R.T., Hendrix S.L., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289 24 (2003) 3243-3253
13. Stefanick M.L., Anderson G.L., Margolis K.L., et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295 14 (2006) 1647-1657
14. Reeves G.K., Beral V., Green J., et al. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7 11 (2006) 910-918
15. Velthuis-Te Wierik E.J., Hendricks P.T., and Martinez C. Preferential prescribing of tibolone and combined estrogen plus progestogen therapy in postmenopausal women. Menopause 14 3 Pt 1 (2007) 518-527
16. Gompel A., Siromachkova M., Lombet A., et al. Tibolone actions on normal and breast cancer cells. Eur J Cancer 36 Suppl. 4 (2000) S76-S77
17. Kubista E., Planellas Gomez J.V., Dowsett M., et al. Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial. Clin Cancer Res 13 14 (2007) 4185-4190
18. Cummings S.R. LIFT study is discontinued (letter). BMJ 332 (2006) 667
19. Cummings S.R., Ettinger B., Delmar P.D., et al. The effects of tibolone in older postmenopausal women. N Engl J Med 359 7 (2008) 697-708
20. Kenemans P., Kubista E., Foidart J.M., et al. Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients-design and baseline data 'LIBERAL' trial. Breast 16 Suppl 2 (2007) S182-S189
21. Ravdin P.M., Cronin K.A., Howlader N., et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356 16 (2007) 1670-1674
22. Holmberg L., Iversen O.E., Rudenstam C.M., et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 100 7 (2008) 475-482
23. von Schoultz E., Rutqvist L.E., and and the Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 97 7 (2005) 533-535
24. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 88 (2002) 321-333
25. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
26. Shumaker S.A., Legault C., Kuller L., et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291 (2004) 2947-2958